Lv11
40 积分 2024-03-11 加入
Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice
2小时前
待确认
Interchangeability of immune checkpoint inhibitors: an urgent need for action
26天前
已完结
A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
29天前
已完结
Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
1个月前
已关闭
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
1个月前
已完结
Cancer incidence and mortality in China, 2022
1个月前
已完结
Origin of Murine B Cell Lineages
1个月前
已完结
Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy
2个月前
已完结
CAR T cell combination therapies to treat cancer
3个月前
已完结
Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy
3个月前
已完结
皖公网安备34019202002308
